High antibody concentrations in aqueous compositions are becoming increasingly important in the pharmaceutical industry in order to deliver the required high dose in as small a volume as possible. However, higher concentrations lead to an increased viscosity, affecting both production processes (pumping, filling, and filtration) and the ability to deliver such compositions (through a syringe or auto-injector). The nature of the interactions of the monoclonal antibodies (proteins) at the origin of the observed viscosity, are not fully understood yet, making its control difficult.

More information: Proposition_These_Sanofi_2015-1